Immune escape of AKT overexpressing ovarian cancer cells

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1630-1635

  Hahne, Jens C ^a   Meyer, Susanne R ^a   Gambaryan, Stepan ^b   Walter, Ulrich ^c   Dietl, Johannes ^a   Engel, Jörg B ^d   Honig, Arnd ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

AKT; Natural killer cells; Ovarian cancer; Platinum resistance

Indexed keywords

CISPLATIN; NATURAL KILLER CELL RECEPTOR; PROTEIN KINASE B;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INTERACTION; CELL KILLING; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE;

APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KILLER CELLS, NATURAL; OVARIAN NEOPLASMS; PLATINUM; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84875994396     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1846     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS and Facchini G: Chemotherapy in epithelial ovarian cancer. Cancer Lett 303: 73-83, 2011.
3. Gonzalez-Martin AJ: Medical treatment of epithelial ovarian cancer. Expert Rev Anticancer Ther 4: 1125-1143, 2004. (Pubitemid 39646566)
4. Matsuo K, Lin YG, Roman LD and Sood AK: Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19: 1339-1354, 2010.
5. Lanier LL: NK cell recognition. Annu Rev Immunol 23: 225-274, 2005. (Pubitemid 40563170)
6. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002. (Pubitemid 35363648)
7. Orr MT and Lanier LL: Natural killer cell education and tolerance. Cell 142: 847-856, 2010.
8. Smyth MJ, Dunn GP and Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50, 2006. (Pubitemid 43765795)
9. Altomare DA, Wang HQ, Skele KL, et al: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004. (Pubitemid 39093031)
10. Cheng JQ, Lindsley CW, Cheng GZ, Yang H and Nicosia SV: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492, 2005. (Pubitemid 41637988)
11. Steelman LS, Chappell WH, Abrams SL, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3: 192-222, 2011.
12. Levine DA, Bogomolniy F, Yee CJ, et al: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11: 2875-2878, 2005. (Pubitemid 40525186)
13. Benedetti V, Perego P, Luca Beretta G, et al: Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 7: 679-687, 2008. (Pubitemid 351482150)
14. Engel JB, Schonhals T, Hausler S, et al: Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 283: 603-610, 2011.
15. Santiskulvong C, Konecny GE, Fekete M, et al: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17: 2373-2384, 2011.
16. Westfall SD and Skinner MK: Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol Cancer Ther 4: 1764-1771, 2005. (Pubitemid 41685311)
17. Hahne JC, Honig A, Meyer SR, et al: Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncol Rep 28: 2023-2028, 2012.
18. Behrens BC, Hamilton TC, Masuda H, et al: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418, 1987. (Pubitemid 17009602)
19. Valiante NM, Rengaraju M and Trinchieri G: Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 145: 187-198, 1992.
20. Sheehy ME, McDermott AB, Furlan SN, Klenerman P and Nixon DF: A novel technique for the fluorometric assessment of T lymphocytic antigen specific lysis. J Immunol Methods 249: 99-110, 2001. (Pubitemid 32171963)
21. Jesnowski R, Backhaus C, Ringel J and Lohr M: Ribosomal highly basic 23-kDa protein as a reliable standard for gene expression analysis. Pancreatology 2: 421-424, 2002. (Pubitemid 34920733)
22. Caligiuri MA: Human natural killer cells. Blood 112: 461-469, 2008.
23. Vivier E, Raulet DH, Moretta A, et al: Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49, 2011.
24. Lanier LL: Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502, 2008. (Pubitemid 351560518)
25. Moretta L, Biassoni R, Bottino C, Mingari MC and Moretta A: Human NK-cell receptors. Immunol Today 21: 420-422, 2000.
26. Bellucci R, Nguyen HN, Martin A, et al: Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest 122: 2369-2383, 2012.
27. Boutet P, Agüera-Gonza'lez S, Atkinson S, et al: Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182: 49-53, 2009.
28. Waldhauer I, Goehlsdorf D, Gieseke F, et al: Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68: 6368-6376, 2008.
29. Okita R, Mougiakakos D, Ando T, et al: HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 188: 2136-2145, 2012.